This article was originally published in The Gray Sheet
Executive SummaryReceives marketing clearance in Canada for the BiliCheck non-invasive bilirubin analyzer, which is designed to replace heel stick blood tests for infant jaundice. The device, which began international sales in May, shines, collects and analyzes light from the infant's forehead to test for jaundice regardless of the infant's skin color, gestational age or post-natal age, the company says. SpectRx expects to file a 510(k) for the product this summer
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.